- Company
- Keytruda leads the market for 3 consecutive years
- by Chon, Seung-Hyun Feb 22, 2023 05:54am
- The immuno-oncology drug Keytruda has topped the rank in pharmaceutical sales for 3 consecutive years. Also, new drugs from multinational pharmaceutical companies, such as Gardasil 9, Prolia, Opdivo, and Dupixent showed strong growth and joined the KRW 100 billion club after exceeding KRW 100 billion in sales last year. On the 22nd, accordin
- Company
- GC Biopharma receives WHO Pre-Qualification for Barycela
- by Kim, Jin-Gu Feb 21, 2023 05:52am
- GC Biopharma announced that the World Health Organization (WHO) has granted prequalification (PQ) for its varicella vaccine, Barycela. Vaccines that receive the WHO prequalification decision after a review of their safety and efficacy become eligible for procurement by the United Nations agencies to be used in national immunization progra
- Company
- 3rd PARPi Talzenna may be prescribed at hospitals in Korea
- by Eo, Yun-Ho Feb 21, 2023 05:52am
- Korea’s third PARP inhibitor, ‘Talzenna’ can now be prescribed at general hospitals in Korea. According to industry sources, Pfizer Korea’s breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) treatment ‘Talzenna (talazoparib)' passed the drug committee reviews of various medical institutions in Korea, including the National Can
- Company
- Organon ‘Samsung’s Humira biosimilar to make KRW 100 billi
- by Jung, Sae-Im Feb 20, 2023 05:53am
- Samsung Bioepeis’ U.S partner Organon projected that the sales of the company’s Humira biosimilar will reach a maximum of KRW 123.5 billion in the first year of its release. On the 16th (local time), Organon projected so while presenting its full-year 2022 financial results, announcing that the company “will be launching the Humira bio
- Company
- Novartis’s Jakavi makes a step towards reimb for GvHD
- by Eo, Yun-Ho Feb 20, 2023 05:52am
- ‘Jakavi’ is now one step closer to extending reimbursement to Graft versus Host Disease (GvHD) in Korea. According to industry sources, Novartis Kroea’s Jakavi (ruxolitinib) recently passed deliberation by the Drug Reimbursement Evaluation Standard Subcommittee. The next step is for the drug to be reviewed by the Drug Reimbursement Eva
- Company
- Leclza’s partner ‘Rybrevant’ lands in Big 5 hospitals
- by Eo, Yun-Ho Feb 17, 2023 05:50am
- The anticancer drug Rybrevant which targets a small number of lung cancer patients has landed at general hospitals in Korea. According to industry sources, Janssen Korea’s Rybrevant (amivantamab), which is used to treat EGFR exon 20 insertion non-small-cell lung cancer (NSCLC) that is insensitive to currently available EGFR tyrosine kin
- Company
- Samsung Bioepis Soliris patent partially invalidated
- by Kim, Jin-Gu Feb 16, 2023 05:52am
- Samsung Bioepis succeeded in partially invalidating the 'Solaris patent. A blue light has been turned on for the release of the Soliris biosimilar this year. According to the pharmaceutical industry on the 13th, the Korean Intellectual Property Tribunal ruled in favor of Samsung Bioepis and ruled in favor of Samsung Bioepis in the invalidatio
- Company
- Open Innovation Trend
- by Jung, Sae-Im Feb 16, 2023 05:52am
- China is pushing for a policy to restrict its biopharmaceutical technology from escaping abroad. In the pharmaceutical industry, where open innovation has become a trend, the U.S. and China are taking the opposite step by fighting for technological supremacy. According to a report published by the Bioeconomic Research Center of the Korea
- Company
- Sorrento Theraputics Inc. filed for bankruptcy protection
- by Hwang, Jin-joon Feb 16, 2023 05:51am
- Sorrento Theraputics Inc., a U.S. bio company invested by Yuhan Corporation, filed for bankruptcy protection in the Southern Texas Bankruptcy Court. Bankruptcy protection is a system similar to Korean court receivership. Sorrento Theraputics Inc. recently lost a damage suit worth 222 billion won, resulting in a short-term cash liquidity crisi
- Company
- Exports of Dong-A ST’s anemia biosimilar exceed KRW 10 bil
- by Chon, Seung-Hyun Feb 16, 2023 05:51am
- The first biosimilar developed by Dong-A ST has made over KRW 10 billion in exports for 2 consecutive years. The cumulative export sales amount of the drug reached KRW 35.6 billion only 3 years after the drug entered the Japanese market. According to Dong-A ST on the 1st, the overseas sales of ‘Darbepoetin-α’ last year recorded KRW 13.3 bi
